Clinical Trial Update: Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating AMD3100 (Plerixafor) in combination with Rituximab in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Mozobil (plerixafor)
• Rituxan (rituximab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Status: COMPLETED